Rockwell Medical Inc - Company Profile
Powered by 
All the data and insights you need on Rockwell Medical Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Rockwell Medical Inc Strategy Report
- Understand Rockwell Medical Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Rockwell Medical Inc (Rockwell) is a biopharmaceutical company that focuses on the development, manufacture and distribution of products for the treatment of chronic kidney disease, iron deficiency, end-stage renal disease and hemodialysis. The company’s major products include Triferic, Dialysate Triferic, citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dry acid concentrate mixer, renalpure, and sterilyte bicarbonate concentrate, hemodialysis concentrates, dialysis kits and ancillary products, among others. It is also investigating Triferic for peritoneal dialysis, total parenteral nutrition, cardiovascular disease and treating cancer patients with iron deficiency. The company markets products through distributors in the US and other countries. Rockwell is headquartered in Hackensack, New Jersey, the US.
Headquarters
United States of America
Address
30142 Wixom Road, Michigan, 48393
Website
www.rockwellmed.com
Telephone
1 248 9609009
No of Employees
253
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RMTI (NASD)
Revenue (2021)
$72.8M
17.6%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
42.8%
(2021 vs 2020)
Market Cap*
$44.3M
Net Profit Margin (2021)
XYZ
51.4%
(2021 vs 2020)
* As of and is in US$
Rockwell Medical Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Triferic (Ferric Pyrophosphate Citrate) | RenalPure |
| Dialysate Triferic | SteriLyte |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Innovates Life Sciences Lending Fund to create, produce, market, and supply a range of haemodialysis products to dialysis providers across the globe. |
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Centers to provide dialysis, home dialysis, training, education support, and nutrition counseling to individuals with kidney disease and kidney failure. |
| 2023 | Contracts/Agreements | In September, the company entered into an agreement with Sanderling Renal Services to provide center, home dialysis and renal telemedicine services focusing on patients in rural and underserved communities across the United States. |
Competitor Comparison
| Key Parameters | Rockwell Medical Inc | American Renal Associates Holdings Inc | Atlantic Dialysis Management Services LLC | Dialysis Clinic Inc | Fresenius Medical Care North America |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Wixom | Beverly | Ridgewood | Nashville | Waltham |
| State/Province | Michigan | Massachusetts | New York | Tennessee | Massachusetts |
| No. of Employees | 253 | 4,977 | - | - | - |
| Entity Type | Public | Private | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert S. Radie | Chairman | Executive Board | 2022 | 59 |
| Mark Strobeck | Director; President; Chief Executive Officer | Executive Board | 2022 | 52 |
| Megan Timmins | Chief Legal Officer; Secretary; Executive Vice President | Senior Management | 2021 | 50 |
| Marc Hoffman, M.D. | Chief Medical Officer | Senior Management | 2019 | 62 |
| Heather Hunter | Senior Vice President; Chief Corporate Affairs Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer